Asset profile
Ninerafaxstat · IMB-101
Small molecule
Evidence outlook · lead readout
NCT04826159 · Type 2 Diabetes, Diabetic Cardiomyopathies, HFpEF - Heart Failure With Preserved Ejection Fraction
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT04826159: Every participant received the drug in this open-label study with no placebo or comparator arm, so no attributable treatment effect can be established, and the primary measure was a cardiac energy-metabolism biomarker rather than a clinical outcome; results have not yet been reported.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.